Functional dyspepsia (FD) is characterized by chronic upper abdominal discomfort, including epigastric pain or burning sensation, early satiety, or postprandial fullness, without any identifiable organic cause, affecting a substantial portion of the global population.Current treatment strategies often involve proton pump inhibitors (PPIs), tricyclic antidepressants (TCA) or histamine-2 receptor antagonists, and prokinetic agents, yet these approaches do not universally alleviate symptoms for all patients.The need for alternative therapies is underscored due to the limitations of conventional medical treatments, including their variable efficacy and potential side effects leading to patient dissatisfaction. The combination of papain and alpha-amylase presents a novel therapeutic avenue. Papain, a proteolytic enzyme, has been shown to aid in protein digestion, while alpha-amylase facilitates carbohydrate breakdown. This dual action could address the digestive inefficiencies often experienced by patients with FD, particularly those with enzyme deficiencies. Sathiraju et al. reported that enzyme supplementation can improve gastrointestinal (GI) function and symptom relief, suggesting that a fixed-dose combination could enhance treatment outcomes. Furthermore, the aging population is particularly susceptible to deficiencies of enzymes responsible for physiological processes, leading to different health issues, the most common being FD. The combination of papain and alpha-amylase can potentially address these deficiencies in the aging population frequently experiencing dyspeptic symptoms.6 In addition, the real-world effectiveness of such combinations is critical to evaluate, as clinical trials often do not fully capture the complexities of everyday patient experiences. Observational studies have highlighted the importance of understanding how treatments perform outside controlled environments, where factors such as adherence, lifestyle, and co-morbidities play significant roles. By focusing on a real-world effectiveness study, the proposed research aims to assess the effectiveness and safety of a fixed-dose combination of papain and alpha-amylase in patients with FD. The findings could contribute significantly to the field of gastroenterology by offering a new, effective treatment option for patients suffering from this challenging condition. |